TCRT Alaunos Therapeutics, Inc.

Alaunos Therapeutics Inc, formerly ZIOPHARM Oncology Inc, is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens (neoAg) arising from genomic mutations.

As of 07/01/2022     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  08/24/2005
Outstanding shares:  215,950,561
Average volume:  5,553,614
Market cap:   $267,778,696
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      B0HZZ46
Valuation   (See tab for details)
PE ratio:   -12.35
PB ratio:   4.81
PS ratio:   672.81
Return on equity:   -136.36%
Net income %:   -16,830.40%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy